The Global Autoimmune Polyglandular Syndrome Type 1 Market is driven by increasing prevalence of APS-1

APS-1 is caused due to mutations in the AIRE gene which leads to dysfunctional immune system. Symptoms of APS-1 include chronic infections, weakness, fatigue, seizures, low blood calcium levels, and others. For the treatment of APS-1, patients are generally prescribed replacement therapies such as corticosteroids, calcitriol or calcium supplements. Due to the rareness and complexity of the condition, APS-1 poses many diagnostic and management challenges.

The Global Autoimmune Polyglandular Syndrome Type 1 Market is estimated to be valued at US$ 257 MN in 2024 and is expected to exhibit a CAGR of 3.1% over the forecast period 2024 to 2031.

Key Takeaways

Key players operating in the Global Autoimmune Polyglandular Syndrome Type 1 are Pfizer Inc., GlaxoSmithKline plc, Novartis AG, Mylan N.V., Teva Pharmaceutical Industries Ltd., Sanofi, F. Hoffmann-La Roche Ltd., Zydus Cadila, Lupin, Amneal Pharmaceuticals LLC., Cipla Inc., Aurobindo Pharma, Glenmark Pharmaceuticals Limited, Eli Lilly and Company, Sun Pharmaceutical Industries Ltd., Allergan, Bristol-Myers Squibb Company, Takeda Pharmaceutical Company Limited, Abbott, and LEO Pharma A/S. The growing prevalence of APS-1 and increasing awareness about signs and symptoms of the rare disease are fueling the demand in the market. Moreover, several autoimmune disorders are being diagnosed at a younger age which is further driving the market growth. The key market players are focused on expanding their presence globally especially in developing regions to tap the market potential.

Market Drivers
The increasing prevalence of Global Autoimmune Polyglandular Syndrome Type 1 Market Size globally is a major driver for the market. As per recent studies, the estimated prevalence of APS-1 is 1-2 cases per million populations. Additionally, rising investments in research and development of novel treatment therapies are also propelling the market growth. Expanding applications of hormonal therapies and ongoing clinical trials to evaluate safety and efficacy of various drugs are expected to boost the autoimmune polyglandular syndrome type 1 market over the forecast period.

Current geopolitical situation is impacting the growth of Global Autoimmune Polyglandular Syndrome Type 1 Market:

The ongoing geopolitical tensions and conflicts across several parts of the world are adversely impacting the growth of the global autoimmune polyglandular syndrome type 1 market. The ongoing Russia-Ukraine war has disrupted international trade and global supply chains. Russia and Ukraine are major suppliers of raw materials required for manufacturing drugs for the treatment of autoimmune polyglandular syndrome type 1. The restrictions on trade and export from these countries due to the war is leading to shortage of essential materials and hike in prices, adversely impacting the production and supply of drugs globally.

Similarly, tensions between China and western nations are negatively impacting trade relations and investments. China is a major market for autoimmune disease treatment drugs. Restrictions on trade and businesses between China and western countries will hamper overall demand growth. Geopolitical instabilities and conflicts in the Middle East are also contributing to rising fuel and transportation costs globally. This is increasing the overall cost of drugs supply and making treatment more expensive.

The companies operating in the market need to diversify their supplier base and look for alternative sources to mitigate risks arising from geopolitical tensions. Contract manufacturers may look to establish facilities in different geographic regions to reduce dependency on single or few regions. The companies also need to explore opportunities in relatively stable markets and focus on cost optimization to offset rising costs due to geopolitical issues.